Hope for LPR

N-Zyme Biomedical seeks to provide a much-needed, safe, effective and efficient treatment for the millions of people in the US and worldwide that suffer from LPR.

Drug development for LPR

Despite the high prevalence of LPR, socioeconomic cost and burden on quality of life, there is currently no effective medical therapy. Pepsin, detected in the airway of patients with LPR and now known to cause inflammation and promote disease independent of gastric acid, is a key therapeutic target.  Our cutting-edge research demonstrates fosamprenavir binds to and inhibits pepsin, preventing pepsin-mediated inflammation and tissue damage. N-Zyme is developing a sustained-release oral formulation of fosamprenavir for the treatment of reflux.  Furthermore, an innovative delivery approach will provide local delivery of a low dose of fosamprenavir direct to the throat. These oral and dry powder inhaler medications will be the first safe, effective, and efficient treatments for the millions of people that suffer from LPR, addressing a significant unmet clinical need.

» What is LPR?
Development Pipeline

NZYM-001

PRE-CLI.
PHASE 1
PHASE 2
PHASE 3
FDA REV.

Therapeutic area: Reflux

Phase: III

Program: NZYM-001 (Oral suspension pepsin inhibitor)

Indication: Laryngopharyngeal Reflux (LPR)

NZYM-002

PRE-CLI.
PHASE 1
PHASE 2
PHASE 3
FDA REV.

Therapeutic area: Reflux

Phase: Preclinical

Program: NZYM-002 (Inhaled pepsin inhibitor)

Indication: Laryngopharyngeal Reflux (LPR)

PATENTS

U.S. Patent Application No. 63/392,929
Filed July 28, 2022

Sustained-release oral Fosamprenavir for the treatment of reflux

Inventors: Nikki Johnston and Franco Gennaro Vigile
Applicants: The Medical College of Wisconsin, Inc. and N-Zyme Biomedical Inc.

International Patent Application: PCT/US2021/027758
FILED April 16, 2021

Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux

Inventors: Nikki Johnston
Applicants: The Medical College of Wisconsin, Inc.

NEW ORAL SUSTAINED-RELEASE FORMULATION OF Fosamprenavir

Our new, sustained-release oral fosamprenavir formulation contains sodium alginate to increase muco-adhesion and prolong esophageal retention and contact time. Local esophageal delivery of a pepsin inhibitor such as fosamprenavir is expected to benefit to the ~50% of LPR patients that have GERD.

N-Zyme Biomedical’s Co-Founder and Chief Scientific Officer, Dr. Nikki Johnston, has been selected as a 2021 Falk Medical Research Trust Catalyst Award recipient.

This award comes with a grant that will go towards the drug reformulation process.

Get Informed

Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.

Thank you for joining us.
Something went wrong. Please contact us on info@nzymebiomedical.com
© 2021 N-Zyme Biomedical Inc.
All Rights Reserved